{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:22:58Z","timestamp":1775190178109,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"9210","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.1016\/s0140-6736(00)02074-2","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T22:28:39Z","timestamp":1027636119000},"page":"1176-1178","source":"Crossref","is-referenced-by-count":293,"title":["The taxanes: an update"],"prefix":"10.1016","volume":"355","author":[{"given":"John","family":"Crown","sequence":"first","affiliation":[]},{"given":"Michael","family":"O'Leary","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(00)02074-2_bib1","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomised study of cisplatin versus paclitaxel versus ciplatin and paclitaxel in patients with suboptimul stage III or IV ovarian cancer: a Gynecologic Oncology Group Study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1993.11.10.1943","article-title":"Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer","volume":"11","author":"Reichman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.1996.14.1.58","article-title":"Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer","volume":"14","author":"Hudis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib6","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.1999.17.11.3403","article-title":"Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol","volume":"17","author":"Smith","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib7","first-page":"110a","article-title":"Final results: randomized phase III trial of paclitaxel by 3 hour versus 96 hour infusion in patients (pts) with metastatic breast cancer (MBc): the long and the short of it","volume":"17","author":"Holmes","year":"1998","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib8","doi-asserted-by":"crossref","first-page":"s75","DOI":"10.1016\/0959-8049(95)95598-Z","article-title":"A multi-center randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)","volume":"31A","author":"Peretz","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0140-6736(00)02074-2_bib9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1996.14.6.1858","article-title":"Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer","volume":"14","author":"Nabholtz","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib10","first-page":"101a","article-title":"Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: results from CALGB 9342","volume":"17","author":"Winer","year":"1998","journal-title":"Proc ASCO"},{"issue":"suppl 8","key":"10.1016\/S0140-6736(00)02074-2_bib11","first-page":"33","article-title":"Phase III randomized trials of docetaxel in patients with metastatic breast cancer","volume":"26","author":"Crown","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib12","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1999.17.11.3412","article-title":"Prospective evaluation of paclitaxel versus combination therapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer","volume":"17","author":"Buzdar","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib13","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","article-title":"Paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(00)02074-2_bib15","first-page":"12","article-title":"Phase III study: Taxotere* (TXT) versus 5-Fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT) (preliminary results)","volume":"9","author":"Monnier","year":"1998","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(00)02074-2_bib16","doi-asserted-by":"crossref","first-page":"s246","DOI":"10.1016\/S0959-8049(99)81396-3","article-title":"Taxotere (TXT) versus best supportive care (BSC) in chemonaive patients with unresectable non-small cell lung cancer (NSCLC): final results of the phase III study","volume":"35","author":"Roszkowski","year":"1999","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(00)02074-2_bib17","first-page":"1","article-title":"Phase III study of paclitaxel (taxol) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC)","volume":"9","author":"Thatcher","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib18","first-page":"463a","article-title":"Randomized study of taxotere (TAX) versus best support care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib19","first-page":"491a","article-title":"Quality of life (QOL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy","volume":"18","author":"Dancey","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib20","first-page":"460c","article-title":"Phase III trial of docetaxel 100 mg\/m2 or 75 mg\/m2 vs vinorelbine\/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (PBC)","volume":"18","author":"Frank","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(00)02074-2_bib22","first-page":"361a","article-title":"Updated analysis shows a highly significantly improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC GCCGC, NOCOVA, NCIC CTG and Scottish Intergroup Trial","volume":"17","author":"Stuart","year":"1998","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib23","first-page":"356a","article-title":"Randomized phase III study of cisplatin (CIS)\/paclitaxel (PAC) versus carboplatin (CARBO)\/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158)","volume":"18","author":"Ozols","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib24","first-page":"356c","volume":"18","author":"Harper","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib25","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dosefinding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib26","first-page":"1a","article-title":"Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin+paclitaxel (A+T) as first-line therapy for matastatic breast cancer (MBC): an intergroup trial","volume":"16","author":"Sledge","year":"1997","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib27","first-page":"601","article-title":"Mitoxantrone+paclitaxel (NT) versus paclitaxel (T) alone for metastatic breast cancer (MBC)","volume":"16","author":"Harvey","year":"1997","journal-title":"Proc ASCO"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(00)02074-2_bib28","doi-asserted-by":"crossref","first-page":"s314","DOI":"10.1016\/S0959-8049(99)81676-1","article-title":"Randomized open-label phase III multicenter trial comparing TAXOL\u00ae\/doxorubicin (AT) versus 5-fluorouracil\/doxorubicin and cyclophophamide (FAC) as a first line treatment for patients with metastatic breast cancer","volume":"35","author":"Pluzzanska","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0140-6736(00)02074-2_bib29","first-page":"127a","article-title":"A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC","volume":"18","author":"Nabholtz","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.1996.14.7.1993","article-title":"Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity","volume":"14","author":"Wasserheit","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib31","first-page":"101a","article-title":"Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)","volume":"17","author":"Henderson","year":"1998","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib32","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","article-title":"Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers","volume":"18","author":"Pegram","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/S0140-6736(00)02074-2_bib33","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(00)02074-2_bib34","first-page":"127a","article-title":"Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)","volume":"18","author":"Norton","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib35","first-page":"461a","article-title":"Two year survival and prognostic factors for overall survival in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group experience","volume":"17","author":"Kim","year":"1998","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib36","first-page":"454a","article-title":"Phase III comparative study of high-dose cisplatin (HD-Cis) versus a combination of paclitaxel (tax) and cisplatin (cis) in patients with advanced non-small cell lung cancer","volume":"17","author":"Gatzemeier","year":"1998","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib37","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.1998.16.6.2133","article-title":"Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"16","author":"Giaccone","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib38","first-page":"455c","article-title":"Randomised phase III trial comparing cisplatin\/etoposide versus carboplatin\/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)","volume":"17","author":"Belani","year":"1998","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib39","first-page":"461a","article-title":"A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) Trial","volume":"18","author":"Kelly","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib40","first-page":"461a","article-title":"Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial","volume":"18","author":"Georgoulias","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(00)02074-2_bib41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","article-title":"Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer","volume":"17","author":"Petrylak","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(00)02074-2_bib42","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase III trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(00)02074-2_bib43","doi-asserted-by":"crossref","first-page":"s232","DOI":"10.1016\/S0959-8049(99)81330-6","article-title":"Feasibility of an accelerated multi-cycle high-dose chemotherapy regimen including high-dose thiotepa for patients (pts) with poor-risk ovarian cancer (OC)","volume":"35","author":"Crown","year":"1999","journal-title":"Eur J Cancer"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673600020742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673600020742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,14]],"date-time":"2019-04-14T11:52:37Z","timestamp":1555242757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673600020742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":43,"journal-issue":{"issue":"9210","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["S0140673600020742"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(00)02074-2","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}